Blog — Peptide Initiative — Peptide Therapy Guide

For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Peptide Database

Peptide Initiative Blog

The Journal.

Index 202626 Articles

Our take on Shawn Ryan Show guest, Louisa Nicola's comments about peptides.

Suppressed by Design: The Power Dynamics Behind Peptide Restrictions

05.15.2026 · Hot Topic

Did RFK finally do what he promised to do about peptide regulation?

04.02.2026 · Legislation

Why do peptides feel sketchy?

03.29.2026 · Hot Topic

Mitochondrial Peptides

02.26.2026 · Anti-Aging & Longevity

Senolytic Peptides: The Science Behind Zombie Cell Removal

02.25.2026 · Anti-Aging & Longevity

Zombie Cells & Senolytic Peptides: Rewriting Aging Rules

Selank and the future in Mental Health Treatment

12.28.2025

Advanced Protocol Cycling: Long-Term Optimization and Maintenance Strategies

12.22.2025 · Legislation

Synergy Optimization: Peptide and Supplement Integration Protocols

Cognitive Enhancement Stack: Nootropic Peptide Protocol Implementation

Gut Restoration Protocol: Healing and Optimization Stack Implementation

Cellular Regeneration Protocol: Anti-Aging Stack with Epithalon, GHK-Cu, and NAD+

Stay in the loop.

The latest peptide research, clinical insights, and guides — delivered to your inbox.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Research context

Read sources and limitations before applying a claim.

The GLP-1 Blueprint: A Case Study in Regulatory Gatekeeping.

The GLP-1 story is the clearest lens through which to understand the broader peptide suppression dynamic. When semaglutide (Ozempic, Wegovy) shortages emerged in 2022, the FDA permitted compounding pharmacies to fill the gap under a shortage exception. Millions of Americans accessed the medication at a fraction of the branded cost. Then, as Novo Nordisk ramped production and resolved the shortage, the FDA moved quickly to close that door permanently. By early 2025, 503A compounders were legally prohibited from producing semaglutide. By mid-2025, 503B outsourcing facilities followed. The FDA's justification: the shortage was resolved, so the exception no longer applied. But what this framing obscures is the effect — not the cause. The effect was that a billion-dollar drug suddenly had its cheaper competition legally eliminated. Whether that was intent or consequence is a question worth sitting with.

Source: peptideinitiative.com ↗

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →